155 related articles for article (PubMed ID: 2326777)
1. Quantitative comparison of recombinant hirudin's antithrombotic and anticoagulant activities with those of heparin.
Porta R; Pescador R; Mantovani M; Prino G
Thromb Res; 1990 Feb; 57(4):639-43. PubMed ID: 2326777
[No Abstract] [Full Text] [Related]
2. Anticoagulant and antithrombotic action of the factor Xa inhibitor antistasin (ATS).
Hauptmann J; Kaiser B
Thromb Res; 1993 Jul; 71(2):169-74. PubMed ID: 8362380
[No Abstract] [Full Text] [Related]
3. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro.
Hauptmann J; Kaiser B
Blood Coagul Fibrinolysis; 1993 Aug; 4(4):577-82. PubMed ID: 8218854
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin.
Carter CJ; Kelton JG; Hirsh J; Gent M
Thromb Res; 1981 Jan 1-15; 21(1-2):169-74. PubMed ID: 7233399
[No Abstract] [Full Text] [Related]
6. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M; Gustafsson D; Deinum J
Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
[TBL] [Abstract][Full Text] [Related]
7. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides.
Raake W; Klauser RJ; Elling H; Meinetsberger E
Thromb Res; 1989 Dec; 56(6):719-30. PubMed ID: 2561233
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987
[TBL] [Abstract][Full Text] [Related]
10. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant and antithrombotic actions of a semisynthetic beta-1,3-glucan sulfate.
Alban S; Jeske W; Welzel D; Franz G; Fareed J
Thromb Res; 1995 May; 78(3):201-10. PubMed ID: 7631300
[TBL] [Abstract][Full Text] [Related]
12. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Matsumoto Y
Br J Pharmacol; 1998 Jan; 123(1):92-6. PubMed ID: 9484858
[TBL] [Abstract][Full Text] [Related]
14. Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
Hayes JM; Jeske W; Callas D; Iqbal O; Fareed J
Thromb Res; 1996 Apr; 82(2):187-91. PubMed ID: 9163072
[No Abstract] [Full Text] [Related]
15. Potential advantages of direct-acting thrombin inhibitors.
Philippides GJ; Loscalzo J
Coron Artery Dis; 1996 Jul; 7(7):497-507. PubMed ID: 8913677
[No Abstract] [Full Text] [Related]
16. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
Gray E; Padilla A; Barrowcliffe TW
Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
[TBL] [Abstract][Full Text] [Related]
17. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
18. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
19. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo.
Talbot MD; Ambler J; Butler KD; Findlay VS; Mitchell KA; Peters RF; Tweed MF; Wallis RB
Thromb Haemost; 1989 Feb; 61(1):77-80. PubMed ID: 2749592
[TBL] [Abstract][Full Text] [Related]
20. Isolation and Characterization of a Heparin-Like Compound with Potent Anticoagulant and Fibrinolytic Activity from the Clam
Du Z; Jia X; Chen J; Zhou S; Chen J; Liu X; Cao X; Zhong S; Hong P
Mar Drugs; 2019 Dec; 18(1):. PubMed ID: 31861572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
